XTalks

NOVEMBER 6, 2020

Symvivo’s bacTRL Gene Therapy Platform is designed and optimized to address limitations associated with typical vaccines, including the inability to accommodate large or multiple genes, lack of specificity to targeted tissue and poor control over immune response, says the company.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Drug Discovery World

DECEMBER 15, 2022

While viral vectors can be highly active, they can lead to only transient expression (rAAV, AdV), can lead to adverse immune responses (AdV) or can integrate randomly into the genome (LV). Each comes with its own drawbacks, including immunogenicity, size restrictions, and off-target effects 6.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. EMJ Allergy Immunol. 2018; 3: 60-9. J Allergy Clin Immunol.

Trials 52

Trials Production Sales Manufacturing 52